ORGN trades 8156.9% below Wall Street's consensus target of $90.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ORGN achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 23, 2026, Origin Materials, Inc. (ORGN) has a Wall Street consensus price target of $90.00, based on estimates from 6 covering analysts. With the stock currently trading at $1.00, this represents a potential upside of +8156.9%. The company has a market capitalization of $5M.
Analyst price targets range from a low of $90.00 to a high of $90.00, representing a 0% spread in expectations. The median target of $90.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, ORGN trades at a trailing P/E of -0.0x. Analysts expect EPS to grow +79.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
GEVOGevo, Inc. | $346M | $1.42 | $2.75 | +78.6% | Buy | — | 14 |
LNZALanzaTech Global, Inc. | $14M | $6.23 | $5.50 | -8.3% | Hold | — | 4 |
VVOSVivos Therapeutics, Inc. | $3M | $0.43 | — | — | — | — | — |
LOOPLoop Industries, Inc. | $36M | $0.74 | — | — | — | — | — |
BIOXBioceres Crop Solutions Corp. | $24M | $0.38 | — | — | — | — | — |
AVNTAvient Corporation | $3.4B | $37.28 | $46.71 | +24.0% | Buy | 12.2x | 20 |
EMNEastman Chemical Company | $8.2B | $71.96 | $79.89 | +10.2% | Buy | 11.4x | 35 |
CECelanese Corporation | $5.6B | $49.73 | $65.60 | +28.2% | Hold | 8.3x | 37 |
BCYCBicycle Therapeutics plc | $276M | $3.98 | $10.67 | +166.8% | Buy | — | 21 |
PRLBProto Labs, Inc. | $1.9B | $81.68 | $38.50 | -52.5% | Hold | 40.1x | 17 |
Quick answers to the most common questions about buying ORGN stock.
The consensus Wall Street price target for ORGN is $90, representing 8156.9% upside from the current price of $0.9977. With 6 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ORGN has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is mixed, with 3 Hold ratings making up the largest segment. The consensus 12-month price target of $90 implies 8156.9% upside from current levels.
ORGN's current price is $0.9977 with a consensus target of $90 (8156.9% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $90 for ORGN, while the most conservative target is $90. The consensus of $90 represents the median expectation. These targets typically reflect 12-month expectations.
ORGN is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ORGN stock forecast based on 6 Wall Street analysts shows a consensus price target of $90, with estimates ranging from $90 (bear case) to $90 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on ORGN, with a "Buy" consensus rating and $90 price target (8156.9% upside). 3 of 6 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ORGN analyst price targets range from $90 to $90, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $90 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.